alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['Oncogenic Mutations'],"[{'ncitCode': 'C179323', 'drugName': 'Lunresertib'}, {'ncitCode': 'C174206', 'drugName': 'Camonsertib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 880, 'code': '', 'color': 'LightBlue', 'name': '', 'mainType': {'id': None, 'name': 'Ovarian Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Ovary/Fallopian Tube', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],[],"[{'link': 'https://ir.reparerx.com/static-files/c46f541b-554a-4690-90de-e63fa7dea852', 'abstract': 'Yap, T. et al., Abstract# 35396. AACR-NCI-EORTC 2023.'}]","Lunresertib is an orally available, small molecule PKMYT1 inhibitor and camonsertib is an orally available, small molecule ATR inhibitor. There are promising clinical data of response to lunresertib plus camonsertib in patients with PPP2R1A-mutated gynecologic cancers. In the Phase I MYTHIC (NCT04855656) trial of lunresertib plus camonsertib in patients with advanced tumors harboring CCNE1 amplifications, FBXW7 deleterious mutations or PPP2R1A deleterious mutations, the lunresertib plus camonsertib cohort (n=59 [n=17, endometrial; n=13, colorectal; n=11, ovarian; n=3, breast; n=3, lung; n=12, other]) demonstrated an overall response rate of 23.6% in all evaluable patients across tumor types, with a 21.4% response rate in patients with PPP2R1A-mutated tumors and a 38.5% response rate in patients with gynecologic cancers across all dosages (Abstract: Yap, T. et al., Abstract# 35396. AACR-NCI-EORTC 2023. https://ir.reparerx.com/static-files/c46f541b-554a-4690-90de-e63fa7dea852)."
['Oncogenic Mutations'],"[{'ncitCode': 'C179323', 'drugName': 'Lunresertib'}, {'ncitCode': 'C174206', 'drugName': 'Camonsertib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 884, 'code': '', 'color': 'PeachPuff', 'name': '', 'mainType': {'id': None, 'name': 'Endometrial Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Uterus', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],[],"[{'link': 'https://ir.reparerx.com/static-files/c46f541b-554a-4690-90de-e63fa7dea852', 'abstract': 'Yap, T. et al., Abstract# 35396. AACR-NCI-EORTC 2023.'}]","Lunresertib is an orally available, small molecule PKMYT1 inhibitor and camonsertib is an orally available, small molecule ATR inhibitor. There are promising clinical data of response to lunresertib plus camonsertib in patients with PPP2R1A-mutated gynecologic cancers. In the Phase I MYTHIC (NCT04855656) trial of lunresertib plus camonsertib in patients with advanced tumors harboring CCNE1 amplifications, FBXW7 deleterious mutations or PPP2R1A deleterious mutations, the lunresertib plus camonsertib cohort (n=59 [n=17, endometrial; n=13, colorectal; n=11, ovarian; n=3, breast; n=3, lung; n=12, other]) demonstrated an overall response rate of 23.6% in all evaluable patients across tumor types, with a 21.4% response rate in patients with PPP2R1A-mutated tumors and a 38.5% response rate in patients with gynecologic cancers across all dosages (Abstract: Yap, T. et al., Abstract# 35396. AACR-NCI-EORTC 2023. https://ir.reparerx.com/static-files/c46f541b-554a-4690-90de-e63fa7dea852)."
['Oncogenic Mutations'],"[{'ncitCode': 'C179323', 'drugName': 'Lunresertib'}, {'ncitCode': 'C174206', 'drugName': 'Camonsertib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],[],"[{'link': 'https://ir.reparerx.com/static-files/c46f541b-554a-4690-90de-e63fa7dea852', 'abstract': 'Yap, T. et al., Abstract# 35396. AACR-NCI-EORTC 2023.'}]","Lunresertib is an orally available, small molecule PKMYT1 inhibitor and camonsertib is an orally available, small molecule ATR inhibitor. There are promising clinical data of response to lunresertib plus camonsertib in patients with PPP2R1A-mutated solid tumors. In the Phase I MYTHIC (NCT04855656) trial of lunresertib plus camonsertib in patients with advanced tumors harboring CCNE1 amplifications, FBXW7 deleterious mutations or PPP2R1A deleterious mutations, the lunresertib plus camonsertib cohort (n=59 [n=17, endometrial; n=13, colorectal; n=11, ovarian; n=3, breast; n=3, lung; n=12, other]) demonstrated an overall response rate of 23.6% in all evaluable patients (n=55) across tumor types, with a 21.4% response rate in patients with PPP2R1A-mutated tumors and a confirmed partial response in a patient with PPP2R1A-mutated cervical cancer (Abstract: Yap, T. et al., Abstract# 35396. AACR-NCI-EORTC 2023. https://ir.reparerx.com/static-files/c46f541b-554a-4690-90de-e63fa7dea852)."
